United Stock Hits New 52-Week High (UTHR)

NEW YORK ( TheStreet) -- United Therapeutics Corporation (Nasdaq: UTHR) hit a new 52-week high Tuesday as it is currently trading at $56.38, above its previous 52-week high of $56.24 with 7,747 shares traded as of 9:30 a.m. ET. Average volume has been 658,300 shares over the past 30 days.

United has a market cap of $2.79 billion and is part of the health care sector and drugs industry. Shares are up 14.3% year to date as of the close of trading on Monday.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and internationally. The company has a P/E ratio of 11.2, above the average drugs industry P/E ratio of 11.1 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates United as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full United Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.